Wilbanks Smith & Thomas Asset Management LLC Cuts Stock Position in Pfizer Inc. (NYSE:PFE)

Wilbanks Smith & Thomas Asset Management LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 34.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,123 shares of the biopharmaceutical company’s stock after selling 53,218 shares during the quarter. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Pfizer were worth $2,883,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the 3rd quarter worth approximately $30,000. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the period. Mizuho Securities Co. Ltd. purchased a new position in Pfizer during the third quarter valued at $34,000. VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the fourth quarter worth $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.50 during mid-day trading on Thursday, reaching $27.68. The company had a trading volume of 17,334,535 shares, compared to its average volume of 42,279,973. The firm has a market cap of $156.74 billion, a price-to-earnings ratio of 76.56, a PEG ratio of 1.15 and a beta of 0.63. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The business’s 50-day simple moving average is $26.87 and its 200 day simple moving average is $28.25.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the prior year, the firm posted $1.14 EPS. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. On average, research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.07%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Analyst Ratings Changes

Several analysts have recently commented on the company. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $36.53.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.